The deals bring together Avant's ovarian cancer diagnostic, Amarantus' multiple sclerosis and Alzheimer's disease assays, and Theranostics' CLIA lab.
The deal brings together three firms that have struggled to ramp their test businesses in hopes that the combined outfit will be better positioned to succeed.
Avant and Amarantus, which agreed to merge in January, have now signed a deal to acquire Theranostics Health and its CLIA-certified laboratory.
When the merger is complete, Amarantus will own 80 million shares of Avant, representing about 45 percent of the combined company.
The theranostics company has repurchased all securities related to Discover Growth Fund's $5 million investment in April.
Amarantus will use the investment to develop and commercialize its neurology diagnostic products and drug candidates, and for other working capital expenses.
Amarantus will use its LymPro Test to evaluate the pharmacodynamic effect of Anavex 2-73 and Anavex Plus on the expression of the biomarker CD69.
The deal opens the door for Amarantus to license as many as six patents to help diagnose patients at risk of developing Alzheimer's disease.
DioGenix and its MSPrecise NGS test for multiple sclerosis will be merged into Amarantus as a foundational asset of a growing neuro-diagnostic business.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.